MAMMARY
CANCER
The following information is simply
informational. It's intent is not to replace the advice of a
veterinarian nor to assist you in making a diagnosis
of your pet. Please consult with your own veterinary physician for
confirmation of any diagnosis. Your pets life may depend on
it.
(Click on the awareness ribbon to easily navigate to
the area you are interested in)


OVERVIEW *
Did you know that half of all the tumors
in female dogs are preventable breast tumors? Dogs develop breast
cancer because they were not spayed before their first or second
heat period. Intact female dogs are highly prone to developing
breast tumors. In fact, they are seven times more likely to get
breast cancer than a spayed dog. One out of four intact female dogs
over 4 years of age will probably develop one or more breast tumors
along the mammary gland chains. Half of all tumors are malignant and
unfortunately, half to 75% of them will kill the dog by recurrence
or spreading (metastasizing) to the lungs within one to two years.
German Shepherds, Dobies and Nordic Breeds seem to do poorly, while
poodles, terriers and cockers seem to have greater incidence. Sex
hormones produced by canine ovaries during their six-month cycle
cause a harmful sensitization or pre-programming of the breast
tissue. This hormonal influence ultimately causes point mutations in
the genes of the breast tissue cells that dictate tumor growth.
Progesterone and estrogen are the hormones that cause this “field
cancerization” effect. Progesterone therapy may cause breast tumors
in dogs. The sex hormone receptors in canine mammary tumors have not
been good indicators for therapeutic response due to their very low
level of activity. If the tumor has positive estrogen or
progesterone receptors, it tends to be benign. An intact female dog
may develop a tumor in any one of her ten mammary glands and over
half will present with more than one
tumor.
CLINICAL
SIGNS:**
There can be a single or several tumors, and they
can occur in one or more glands. The last two sets of glands (the
4th and 5th glands) are most commonly affected. The tumors can be
firm or soft, well-defined lumps or diffuse swellings. Tumors can be
attached to underlying tissues or moveable, skin-covered or
ulcerated. They can be different sizes, and they may grow slowly or
quite fast. Most dogs are seen by the veterinarian for signs
associated with the primary tumor and are otherwise feeling well. A
few dogs are diagnosed with advanced metastasis (tumors that have
spread to elsewhere in the body, such as the lungs and lymph nodes)
and might be feeling ill from their tumors when they come for
treatment.
DIAGNOSIS/INITIAL
EVALUATION:*
Fine needle aspiration is controversial
for breast tumor classification. I like to perform cytology
on mammary tumors before surgery because it is wise to rule out mast
cell cancer and cystic disease. I recall a case where cytology
proved to be very important. Several years ago, an intact female Maltese was given a poor
prognosis and turned down for breast cancer surgery by a boarded
surgeon’s office. The grief stricken family came in for a second
opinion. The dog had multiple firm nodules along both mammary
chains. During consultation, I aspirated one nodule from every
mammary gland and found cystic fluid in each with no cancer
cells. Some tumors
appear benign and others appear “hot” on the cytology slide. If the tumor appears in
multiple glands and looks “hot” (malignant) on cytology, I recommend
pre-surgical planning for a more extensive surgery such as radical
mastectomy to include the draining lymph nodes. If we educate our
pet owners, they’ll want to discuss the pros and cons of surgery.
STAGING:**
Mammary gland tumors can be either malignant (cancerous) or
benign (non-cancerous) and arise from the different types of tissues
(epithelial or glandular tissues, and mesenchymal or
connective tissues) in the mammary gland. The most common types are
tumors from the glandular tissues and include adenoma,
carcinoma, and adenocarcinoma. Half of all mammary gland
tumors are benign and can be treated successfully with surgery
alone. The other half are malignant and have the potential for
metastasis. The outcome for patients with malignant mammary gland
tumors depends on several factors including tumor type, histologic
grade (appearance of the tumor cells under the microscope and how
similar or dissimilar they are to normal tissues), tumor size, and
tumor stage (presence of regional and distant metastasis).
We recommend that all mammary gland masses are surgically removed
and biopsied to determine the tumor type. Dogs with benign tumors
usually do not require further treatment, but cases with malignant
tumors should be staged (evaluated for metastasis by tests
such as chest X-rays and abdominal ultrasound). Dogs with small
(less than about 1 inch diameter) low histologic grade carcinomas
and adenocarcinomas with no evidence of metastasis may be treated
effectively with surgery alone. Dogs with large or invasive tumors,
high histologic grade, sarcomas (tumors of mesenchymal origin),
lymph node involvement and/or other sites of spread are at risk for
both recurrence of the original tumor and metastasis.
TREATMENT:*
There is no question that all firm breast tumors
should be promptly removed and sent to the lab for biopsy. Mammary
tumors should always be removed because they only get bigger. If the
tumor is smaller than 3 cm in size, the dog will live longer. If the dog is not
spayed, there is now proof that she will benefit by having the
ovaries and uterus removed (OVH). A belated OVH for a tumor-bearing
dog can reduce her chances of masking her tumors with a false
pregnancy. She can also be spared the common problem of infection of
the uterus (pyometra) that follows about a month after estrus. OVH
also eliminates the risk of ovarian and uterine tumors. Whenever
possible, I prefer a wide surgical removal over a conservative
procedure. If a singular mass is presumed to be malignant, I prefer
that the entire tumor is removed with a normal gland above and below
the mass. Since all the breast tissue is pre programmed to make
tumors, I feel that the dog may be truly
better off with the susceptible mammary
tissue being removed; however, the
literature does not suggest this for localized tumors. If the biopsy report shows
that the tumor is malignant and has invaded into the lymph system or
if the surgical margins were dirty, a second surgery is suggested to
get clean margins and the local draining lymph node for biopsy. In
specialized centers, surgery along with intraoperative radiation may
reduce or arrest a vicious cycle of local recurrence. Follow up radiation
therapy to the primary site and draining lymph node may also help
reduce the problem of local recurrence and local metastasis. Sheena, a beautiful brown
Dobie, was presented in distress. The Figuroa family was heart
broken with the news from their referring vet that Sheena could not
be helped with further surgery. Sheena had two rapid recurrences at
the same site and then developed an enlarged right axillary lymph node
that threatened her life. We quickly started Sheena on radiation and
chemotherapy. In February, 2001, Sheena celebrates her 3-year
anniversary.<
For the past 25 years, the
most commonly used chemotherapy protocol for the prevention of
metastases from malignant breast cancer in dogs was Adriamycin at
30mg/M@ LV. every 21 days and oral Cytoxan at 50 mg every other day
for 8 weeks or on day 3-6 of each 21 day cycle. For the past 8
years many oncologists, including myself, prefer to use mitoxantron
(Novantrone™) at 6
mg/M@ as a first choice and then Adriamycin or Carboplatin at
300mg/M@ for resistant
disease.
The selected drug is administered every 21
to 30 days for 4-6 treatments then
every 5- 6 weeks for 4-6 treatments or more depending on the
severity of the malignancy. Treatment with chemotherapy may reduce
the ability of the circulating cancer cells to establish viable
colonies in the lungs.
In my practice, we recommend the
supplements that are shown to reduce the risk of breast
cancer for women: Inositol
hexaphosphate (IP6 derived from rice), 1-3-beta glucan
(derived from yeast) and
[name witheld at request of producer], which contains the
sugar, fucose, which is deficient in
breast and prostate cancer patients. It makes sense to
recommend these products for life
since intact female dogs have the highest incidence of
breast tumors than any other
companion animal and three times the incidence of breast tumors than
women. If these “Chemoprevention” (see VPN, March 2000) supplements
are added tot he diet, they may play a role in the prevention
of recurrent breast tumors in predisposed
dogs.
CLINICAL
TRIALS:
We are not aware of any clinical
trials at this time
CLINICAL TRIAL
RESULTS:***
1: J Vet Intern Med. 2003
Jan-Feb;17(1):102-6.
Influence of
host factors on survival in dogs with malignant mammary gland
tumors.
Philibert JC, Snyder PW, Glickman N, Glickman LT,
Knapp DW, Waters DJ.
Department of Veterinary
Clinical Sciences, Purdue University School of Veterinary Medicine,
West Lafayette, IN, USA.
jphilibert@nevog.com
The
purpose of our study was to determine if specific host factors, such
as age at diagnosis, obesity, and hormone status, influence the
prognosis of canine mammary gland carcinomas and to confirm if
previously reported risk factors (ie, histologic subtype, tumor
size, and World Health Organization [WHO] stage) were important in a
large series of affected dogs. Ninety-nine female dogs with mammary
gland carcinomas, no previous therapy, an excisional biopsy, and
known cause of death were studied. No significant association with
survival was noted for age at diagnosis (chronologic or
physiologic), obesity, or hormone status (ie, spayed versus intact,
regardless of time of being spayed). Of the tumor factors analyzed,
the histologic subtype anaplastic carcinoma (P = .02), WHO stage I
(P = .01), evidence of metastasis at the time of diagnosis (P =
.004), and tumor size of 3 cm or smaller (P = .005) all
significantly influenced survival. Dogs that were classified as
having tumor-related mortality had a shorter postoperative survival
compared to dogs that died of other causes (14 months versus 23
months; P = .03). In conclusion, histologic subtype, WHO stage, and
tumor size remain important prognostic factors in canine mammary
gland tumors. Further study of other prognostic factors is needed to
determine which tumors are adequately addressed with local therapy
only and which dogs may require adjuvant treatment with
chemotherapy.
PMID: 12564734
[PubMed - indexed for MEDLINE]
2. J Vet Intern Med. 2000
May-Jun;14(3):266-70.
Effect of spaying and
timing of spaying on survival of dogs with mammary
carcinoma
Sorenmo KU, Shofer FS, Goldschmidt MH
Department of Clinical Studies and Pathobiology, School of
Veterinary Medicine, University of Pennsylvania, Philadelphia
19104-6010, USA.
The risk of developing mammary gland
tumors in dogs is significantly decreased by ovariohysterectomy at
an early age. However, previous studies have not found a benefit to
ovariohysterectomy concurrent with tumor removal in dogs with
established mammary gland tumors, suggesting that the progression of
these tumors is independent of continued estrogen stimulation. The
purpose of this study was to evaluate the effect of spaying and of
the timing of spaying on survival in dogs with mammary gland
carcinoma. Signalment, spay status and spay age, tumor
characteristics, treatment. survival, and cause of death of 137 dogs
with mammary gland carcinoma were analyzed. The dogs were classified
into 3 groups according to spay status and spay time: intact dogs,
dogs spayed less than 2 years before tumor surgery (SPAY 1), and
dogs spayed more than 2 years before their tumor surgery (SPAY 2).
Dogs in the SPAY 1 group lived significantly longer than dogs in
SPAY 2 and intact dogs (median survival of 755 days, versus 301 and
286 days, respectively, P = .02 and .03). After adjusting for
differences between the spay groups with regard to age, histologic
differentiation, and vascular invasion, SPAY 1 dogs survived 45%
longer compared to dogs that were either intact or in the SPAY 2
group (RR = .55; 95% CI .32-.93; P = .03). This study reveals
ovariohysterectomy to be an effective adjunct to tumor removal in
dogs with mammary gland carcinoma and that the timing of
ovariohysterectomy is important in influencing
survival.
PMID: 10830539 [PubMed - indexed for
MEDLINE]
NOTE: Dr.
Sorenmo and the other oncologists at the MJR-Veterinary Hospital of
the University of Pennsylvania are unable to answer questions
directly from owners. However, please feel free to direct
questions through the veterinary editor of OncoLink. Owners
with questions will either be directed to the appropriate
resources or a new FAQ will be created if the requested
information is not readily
available.
LINKS FOR MORE INFORMATION
ON MAMMARY CANCER:
Angiogenesis Foundation
Wing and Wave
Labradors
VetInfo
The Pet Center (This site is
graphic)
Oncolink
Pet Education.com (By Drs. Foster
& Smith)
ACKNOWLEDGMENTS:
*Many
thanks and acknowledgment to Dr. Alice
Villalobos, Editor-in-Cheif of the American Association of
Human Animal Bond Veterinarians; Animal
Oncology Consultation Service Coast Pet Clinic of Hermosa Beach,
Inc. for enthusiatically granting us permission to use the above
information. To read more about the wonderful work Dr. Villalobos
has done in the field of animal oncology click
here.
**Canine Cancer Awareness gratefully
acknowledges the University of Pennsylvania Cancer Center ( OncoLink) for granting us permission
for the use of the above information.
*** PubMed , Published
for MEDLINE, National Library of
Medicine |